Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer
Status: SUSPENDED
Study type: INTERVENTIONAL
Conditions: Breast Adenocarcinoma|HER2/Neu Negative|Invasive Breast Carcinoma|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7
Interventions: DRUG: Eribulin Mesylate|OTHER: Laboratory Biomarker Analysis|DRUG: Paclitaxel|OTHER: Quality-of-Life Assessment
Sponsor: Academic and Community Cancer Research United
Collaborators: National Cancer Institute (NCI)